Phaseline

Companies › Institut de Recherches Internationales Servier (I.R.I.S.)

Institut de Recherches Internationales Servier (I.R.I.S.): clinical trials, targets and expected readouts

2 active drug programs in 10 registered trials: 5 Phase 1, 3 Phase 3, 2 Phase 2; Oncology, Gastroenterology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Vorasidenib
IDH1/IDH2 inhibitor; Isocitrate dehydrogenase [NADP], mitochondrial inhibitor; Isocitrate dehydrogenase [NADP] cytoplasmic inhibitor
IDH1, IDH2Phase 2Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 Mutation; Severe Hepatic Impairment; Grade 2 Glioma; Astrocytoma, IDH-Mutant, Grade 3 …Nov 2026
BN104
unclear - specific molecular target not stated
–Phase 1ALL, Adult; Menin InhibitorsDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07250633VorasidenibPhase 1Severe Hepatic ImpairmentGastroenterologyNov 2026
NCT06052813BN104Phase 1ALL, AdultOncologyDec 2026
NCT05609994VorasidenibPhase 1Low Grade Glioma of BrainOncologyAug 2027
NCT05484622VorasidenibPhase 1AstrocytomaOncologyAug 2027
NCT06478212VorasidenibPhase 1IDH1-mutant GliomaOncologyNov 2027
NCT07101497BN104Phase 2Menin InhibitorsOncologyDec 2027
NCT04164901VorasidenibPhase 3Grade 2 GliomaOncologyMay 2028
NCT07286292VorasidenibPhase 2Grade 2 Astrocytoma or Oligodendroglioma With an IDH1 or IDH2 MutationOncologyMay 2033
NCT07215910VorasidenibPhase 3Astrocytoma, IDH-Mutant, Grade 3OncologyMay 2033
NCT06809322VorasidenibPhase 3IDH-mutant Grade 2 or 3 AstrocytomaOncologyApr 2035

Targets

IDH1 (1) IDH2 (1)

Companies with the same targets

Servier Eli Lilly Bristol-Myers Squibb Hutchmed Chia Tai Tianqing Pharmaceutical Group Nuvation Bio Kissei Pharmaceutical Servier Affaires Médicales Rigel Pharmaceuticals Servier Bio-Innovation

Companies built like this

Servier Servier Affaires Médicales Zhejiang Doer Biologics Tianjin ConjuStar Biologics Zhejiang Hisun Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.